12/11
07:31 am
cnta
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications [Yahoo! Finance]
Medium
Report
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications [Yahoo! Finance]
12/11
07:00 am
cnta
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Medium
Report
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
12/10
08:43 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $62.00 price target on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $62.00 price target on the stock.
12/9
12:27 am
cnta
Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results [Yahoo! Finance]
Low
Report
Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results [Yahoo! Finance]
12/1
10:19 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at B. Riley from $33.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at B. Riley from $33.00 to $42.00. They now have a "buy" rating on the stock.
11/21
05:30 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/18
10:00 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Guggenheim from $28.00 to $43.00. They now have a "buy" rating on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Guggenheim from $28.00 to $43.00. They now have a "buy" rating on the stock.
11/14
08:21 pm
cnta
Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program [Yahoo! Finance]
Low
Report
Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program [Yahoo! Finance]
11/13
10:48 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Wells Fargo & Company from $30.00 to $35.00. They now have an "overweight" rating on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Wells Fargo & Company from $30.00 to $35.00. They now have an "overweight" rating on the stock.
11/11
08:40 pm
cnta
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
High
Report
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
11/11
04:00 pm
cnta
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
High
Report
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
11/7
02:22 pm
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target lowered by analysts at Wells Fargo & Company from $31.00 to $30.00. They now have an "overweight" rating on the stock.
Neutral
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target lowered by analysts at Wells Fargo & Company from $31.00 to $30.00. They now have an "overweight" rating on the stock.
11/7
08:00 am
cnta
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
High
Report
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
11/5
12:12 pm
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was given a new $30.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was given a new $30.00 price target on by analysts at Truist Financial Corporation.
11/5
07:00 am
cnta
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
Low
Report
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
10/28
06:01 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was given a new $35.00 price target on by analysts at Stephens.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was given a new $35.00 price target on by analysts at Stephens.
10/27
04:00 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at
Wall
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at
Wall
10/19
01:05 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by analysts at
Wal
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by analysts at
Wal
10/11
01:09 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at
Wall
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at
Wall
10/6
09:15 am
cnta
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $28.00 price target on the stock.
Low
Report
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $28.00 price target on the stock.